Welcome to PEGS 365, the always-open digital home for PEGS Boston, PEGS Europe, and PEGS AI. Explore articles, tune into The Chain Podcast, and discover perspectives to inform your work in protein engineering and biologics development. Keep learning between events, and come back for fresh ideas and conversations.
EXPLORE THE ARTICLES
|
EXPLORE INSIGHTS
|
LISTEN TO THE CHAIN PODCAST
Insights from PEGS | AI can generate protein designs faster than laboratories can test them. Explore how rapid expression, quantitative measurements, functional testing, and developability assessment create the experimental feedback needed to guide better protein design decisions and advance more promising biologic drug candidates. more...
October 29, 2026
Insights from PEGS | Improving antibody selectivity means balancing healthy tissue protection with tumor coverage. Explore how affinity tuning, dual targeting, conditional activation, and immune engagement shape that balance, and why stronger designs must preserve activity across the biological variation found in real tumors. more...
October 29, 2026
Perspectives from PEGS | Scientists have discovered that during inflammation, mammalian immune cells can create entirely new messenger RNAs by fusing segments from two different genes into functional chimeric mRNA. Such fused RNAs have been previously associated with DNA damage, but a new study published Sept. 2 in Nature (DOI: 10.1038/s41586-026-10982-x) shows that some protein‑coding chimeric mRNAs are not accidental events caused by disease-causing DNA rearrangements, but in fact have a functional role within the immune system to fight infection. more...
October 29, 2026
Perspectives from PEGS | For years, the story of T cell engagers (TCE) in oncology followed a predictable arc: remarkable results in liquid tumors, stubborn failure in solid ones. The addition of a dedicated TCE track to this year's PEGS Europe reflects a growing conviction in the field that the second half of that story is changing. Dr. Aude Segaliny, founding scientist of Amberstone Biosciences and one of the program's speakers, thinks the timing is right. She has a clear view of why. more...
October 29, 2026
Insights from PEGS | Higher tissue uptake does not always mean better delivery. Explore how molecular size, binding kinetics, receptor trafficking, and retention shape whether biologics reach the right cells and compartments, and how to connect those design choices with the intended therapeutic activity. more...
October 29, 2026
Insights from PEGS | A stronger tumor-killing response is only part of choosing a multispecific architecture. Explore how added functionality, antigen-dependent selectivity, assembly, purification, and developability shape the tradeoffs that determine whether a promising design has a credible path from discovery into therapeutic development. more...
October 29, 2026
Insights from PEGS | Selecting antibody candidates too early can eliminate valuable biology. Explore how preserving functional diversity, testing representative formats, and interpreting developability data carefully can help teams choose molecules with the right mechanism and a stronger path from discovery into therapeutic development. more...
October 29, 2026
